Howard McLeod, Center Director at Center for Precision Medicine and Functional Genomics, shared a post on LinkedIn:
“I have had the privilege of training at, working at, collaborating with, and/or advising many of the National Cancer Institute (NCI) designated centers.
One difference between the good ones and the great ones is the level of contentment with current treatment approaches.
In the context of advanced solid tumors, too often I hear from patients, families or their oncologist that the specialist at XXX center said, ‘we know how to treat that’.
The unsaid part is ‘with yesterday’s guidelines’.
Our best therapies currently provide better outcomes than the previous treatments, but long-term disease control/cure remains elusive.
The great places might also end up giving current guideline therapy, but it will be through frustration and determination to have better options in the future.”
Other articles featuring Howard McLeod on OncoDaily.